Media headlines about Galectin Therapeutics (NASDAQ:GALT) have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Galectin Therapeutics earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.1071218063947 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- 9 Major Stock Movers to Watch for Wednesday (247wallst.com)
- Galectin Therapeutics (GALT) Announces $10M Credit Line from Richard E. Uihlein; Sufficient to Cover Expected Expenditures Into 2019 (streetinsider.com)
- Financial Analysis: Galectin Therapeutics (GALT) vs. Its Rivals (americanbankingnews.com)
- Galectin Therapeutics, Inc. (GALT) Retorts Its Active Position on Unparallel Developments – Stock News Stop (stockmarketstop.com)
- Galectin Therapeutics (GALT) Announces $10M Credit Line from Richard E. Uihlein; Sufficient to Cover Expected … – StreetInsider.com (streetinsider.com)
Several equities analysts have recently issued reports on GALT shares. ValuEngine downgraded shares of Galectin Therapeutics from a “sell” rating to a “strong sell” rating in a report on Thursday, September 21st. Seaport Global Securities reiterated a “buy” rating and issued a $5.00 price target on shares of Galectin Therapeutics in a report on Friday, October 6th. Roth Capital assumed coverage on shares of Galectin Therapeutics in a report on Thursday, October 19th. They issued a “buy” rating and a $8.00 price target on the stock. HC Wainwright increased their price target on shares of Galectin Therapeutics from $3.50 to $6.00 and gave the stock a “buy” rating in a report on Tuesday, November 28th. Finally, Zacks Investment Research upgraded shares of Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a report on Thursday, November 30th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $4.55.
Galectin Therapeutics (NASDAQ:GALT) last issued its quarterly earnings results on Tuesday, November 7th. The company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. analysts expect that Galectin Therapeutics will post -0.52 earnings per share for the current year.
WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Galectin Therapeutics (GALT) Stock Price” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://sportsperspectives.com/2017/12/20/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-galectin-therapeutics-galt-stock-price.html.
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.